A5012308931- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Ovarian cancer diagnosis and treatment
- Hematopoietic Stem Cell Transplantation
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- PI3K/AKT/mTOR signaling in cancer
- Glioma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Chemotherapy-related skin toxicity
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
National Institute of Public Health
2024
National Institute of Oncology
2020-2022
Centrum Onkologii
2012-2018
University of Warmia and Mazury in Olsztyn
2014
Uczelnia Warszawska im. Marii Skłodowskiej-Curie
2012
Cerner (United States)
2008
Greater Poland Cancer Center
2003
Introduction: Primary renal lymphoma is extremely rare, accounting for less than 1% of all lymphomas. Objectives: The aim this study was to describe a group patients with primary diagnosed in hematology and oncology centers aligned the Polish Lymphoma Research Group (PLRG). Patients methods: This retrospective analysis adult at PLRG centers. Results: Thirty-two were seven over 24 years (2000–2023). most common type diffuse large B-cell (DLBCL). median progression-free survival (PFS) after...
8005 Background: PD-1 blockade via pembro monotherapy showed antitumor activity in R/R cHL. KEYNOTE-204 (NCT02684292) was a randomized, international, open-label, phase III study of vs BV Methods: Patients (pts) were aged ≥18 y, post−autologous stem cell transplant (auto-SCT) or ineligible for auto-SCT, and had measurable disease ECOG PS 0 1. BV-naive BV-exposed pts eligible. Pts randomized 1:1 to 200 mg IV Q3W 1.8 mg/kg stratified by prior auto-SCT (yes no) status after 1L therapy (primary...
Abstract T cells from cancer patients are often functionally impaired, which imposes a barrier to effective immunotherapy. Most pronounced the alterations characterizing tumor-infiltrating cells, in renal cell carcinomas includes defective NF-κB activation and heightened sensitivity apoptosis. Coculture experiments revealed that tumor lines induced time-dependent decrease RelA(p65) p50 protein levels within both Jurkat peripheral blood lymphocytes coincided with onset of The degradation...
Abstract Tumors can promote their own progressive growth by inducing T cell apoptosis. Though previous studies suggested that tumor-mediated killing is receptor dependent, we recently showed tumor gangliosides also participate, a notion consistent with reports indicating that, in some types, activate the intrinsic apoptotic pathway stimulating reactive oxygen species production, cytochrome c release, and caspase-9 activation. In this study, used normal peripheral blood cells, as well...
Summary R‐CVP (cyclophosphamide, vincristine, prednisone) and R‐CHOP doxorubicin, prednisone + rituximab) are immunochemotherapy regimens frequently used for remission induction of indolent non‐Hodgkin lymphomas (iNHLs). Rituximab maintenance (RM) significantly improves progression‐free survival (PFS) in patients with complete/partial (CR/PR). Here we report the final results a randomized study comparing to both followed by RM. Untreated need systemic therapy symptomatic progressive iNHLs...
Summary Some patients with relapsed/refractory Hodgkin lymphoma ( HL ) are not considered suitable for stem cell transplant SCT and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks) in 60 (aged ≥18 years) CD30‐positive , history of ≥1 prior systemic chemotherapy regimen, who were unsuitable /multi‐agent chemotherapy. Primary endpoint was overall response rate ORR per independent review facility IRF ). Secondary...
The severe acute respiratory syndrome coronavirus (SARS-CoV-2) has become the cause of a worldwide pandemic, and its clinical infection course in patients with hematological malignancies may be severe. We performed retrospective study on 188 chronic lymphocytic leukemia (CLL) COVID-19 infection. At time 51 (27.1%) were treated Bruton tyrosine kinase inhibitor (BTKi), 46 (24.5%) anti-CD20 antibodies while 37 (19.7%) received venetoclax. In total, 111 (59.0%) required hospitalization 50...
The results of the MURANO trial showed encouraging progression-free survival (PFS) and overall (OS) in relapsed/refractory chronic lymphocytic leukemia (RR-CLL) patients treated with venetoclax-rituximab (VEN-R). A retrospective analysis was performed to evaluate efficacy safety VEN-R within Polish Adult Leukemia Study Group (PALG) centers. study group included 117 RR-CLL (with early relapse after immunochemotherapy or bearing TP53 aberrations) 2019-2023 outside clinical trials. Patients...
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic metabolomic analyses identify common distinct taxonomic configurations among 40, 45, 71, 34, 50, 60, 40 patients with colorectal cancer, stomach breast lung melanoma, lymphoid neoplasms acute myeloid leukemia (AML), respectively, compared the data those from sex- age-matched healthy controls (HC)....
7531 Background: Treatment options are limited for patients (pts) with R/R DLBCL who not candidates autologous stem cell transplant (ASCT). ROR1 is an oncofetal protein pathologically expressed in hematologic malignancies including DLBCL. In the phase 1 first-in-human study (waveLINE-001), ROR1-targeting antibody-drug conjugate zilovertamab vedotin (ZV) showed promising activity and manageable safety The single-arm, open-label, 2 waveLINE-004 (NCT05144841) designed to evaluate of ZV...
This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated received 600 (19 patients) 800 mg (18 oral daily for the initial 5 days 14-day treatment cycles. Objective response rate (ORR) (primary) was 34% reaching disease control 54% patients. Most (69%) showed reduced tumor size [18F]-FDG uptake target...
KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported received ≥1 dose study treatment and completed PRO assessment. The EORTC QoL Questionnaire Core 30...
The first-line obinutuzumab-based immunochemotherapy improves the outcome of patients with follicular lymphoma (FL) compared rituximab-based regimens. However, infusion-related reactions occur in almost half during 1st obinutuzumab administration.The study aimed to evaluate early effectiveness and safety induction regimens a real-world setting.Outcomes diagnosed FL treated between January 2020 September 2021 were analyzed.The group included 143 treatment-naïve FL. median age was 52 years...
Bexarotene, a synthetic retinoid licensed for the treatment of refractory cutaneous T-cell lymphoma (CTCL), has been used clinically in Poland since 2007 21 patients. The objective our retrospective, multicenter study was to evaluate experience with bexarotene therapy, including efficacy, safety, and survival outcomes. We retrospectively identified adult patients who were treated between years 2012. Starting dose 300 mg/m2 per day. analysis included 3 early-stage mycosis fungoides (MF), 16...
Activated regulatory T cells (Tregs) suppress proliferation and differentiation of normal B cells. In our study, allogeneic polyclonal CD4 (+) CD25 Tregs CD127(lo)Tregs expanded in vitro the presence rapamycin low dose IL-2 suppressed 11 out 12 established lymphoma B-cell lines. The effect on survival freshly isolated maintained culture with soluble multimeric CD40L IL-4 was variable across entities. follicular usually decreased cocultures Tregs. Treg chronic lymphocytic leukemia/small...
Abstract Available epidemiological reports on follicular lymphoma (FL) often highlight a significant discrepancy between its high and low incidence rates in Western Eastern Europe, respectively. The reasons behind that difference are not fully understood, but underreporting is typically presumed as one of the main factors. This study aimed to assess FL epidemiology Poland based 2000–2014 data from Polish National Cancer Registry, which has 100% population coverage over 90% completeness...
Background/Objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes. Aims: The aims of this study were assess the following: (1) incidence pneumonia in CLL patients treated venetoclax-based regimens a real-world setting, (2) risk factors for event-free survival (EFS), and (3) overall (OS). Methods: This multicenter included 322 from eight centers. Univariable multivariable analyses (MVA) performed, development during...
Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results treatment 124 patients with PMBL over a period between 2004 and 2017 the use protocol designed for aggressive GMALL/B-ALL/NHL2002 including 6 cycles alternating immunochemotherapy intermediate-dose methotrexate each cycle, reduced total doxorubicin dose (100 mg/m2...
The purpose of the study was to investigate possible association between ERCC2 rs28365048, ERCC5 rs17655, XRCC3 rs861539 and NOS2A rs2297518 polymorphisms with B-cell lymphoma. conducted on 189 patients CD20+ lymphoma 193 controls. genotype frequencies were compared in patient control groups using quantitative polymerase chain reaction, based allelic discrimination analysis. Our results indicated that variation may be significant a population ≥50 years old (OR=2.15; 95% CI, 1.17-3.92;...